Table 2 Univariate and multivariate Cox proportional hazards analysis of OS for the CRC patients in the TCGA cohort (HR: hazard ratio, CI: confidence interval).
From: WBSCR22 confers oxaliplatin resistance in human colorectal cancer
Characteristics | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
p | HR (95% CI) | p | HR (95% CI) | |
Gender | ||||
 Male | 0.197 | 1.000 |  |  |
 Female |  | 0.720(0.437–1.186) |  |  |
Age | ||||
 ≥60 | 0.018 | 1.000 | 0.003 | 1.000 |
 <60 |  | 0.479(0.261–0.879) |  | 0.376(0.199–0.713) |
Primary site | ||||
 Colon | 0.157 | 1.000 |  |  |
 Rectum |  | 0.599(0.295–1.217) |  |  |
Histological type | ||||
 Adenocarcinoma | 0.001 | 1.000 | 0.036 | 1.000 |
 Mucinous adenocarcinoma |  | 0.405(0.234–0.699) |  | 2.075(1.050–4.101) |
TNM stage | ||||
 Stage I + II | 0.00035 | 1.000 | 0.002 | 1.000 |
 Stage III + IV |  | 2.518(1.517–4.179) |  | 2.419(1.376–4.252) |
Venous invasion | ||||
 Negative | 0.002 | 1.000 | 0.235 | 1.000 |
Positive |  | 2.604(1.498–4.527) |  | 1.380(0.607–3.138) |
 Unkonw |  | 1.823(0.939–3.542) |  | 0.401(0.089–1.805) |
Lymphatic invasion | ||||
 Negative | 0.006 | 1.000 | 0.471 | 1.000 |
 Positive |  | 2.314(1.350–3.965) |  | 1.373(0.594–3.173) |
 Unkonw |  | 1.970(0.965–4.020) |  | 2.679(0.516–13.895) |
WBSCR22 | ||||
 Low | 0.001 | 1.000 | 0.005 | 1.000 |
 High |  | 2.471(1.432–4.265) |  | 2.391(1.310–4.365) |
